Vital Therapies provides clinical and regulatory update
Vital Therapies (NASDAQ:VTL) has provided an update on its clinical trial programs and regulatory matters. Currently, 193 of a targeted 200 subjects have been enrolled in VTI-208, the company’s Phase 3...
View ArticleVital Therapies Phase 3 trial hits enrolment target
Vital Therapies (NASDAQ:VTL) has reached the 200 subject enrollment target in VTI-208, its randomized, open-label Phase 3 clinical trial in alcohol induced liver decompensation. “Executing on VTI-208...
View Article
More Pages to Explore .....